Select a cancer type to view all clinical trials for that cancer, or view all currently open clinical trials below.
If you don’t see the cancer type you’re looking for, please contact us here. We may still have relevant trials or be able to assist with your search.
All Current Clinical Trials
| Protocol Number | Cancer Type | Study Name | Intervention | Mechanism of Action | Recruitment Status | Sponsor | Clinical.Trials.gov ID | Click to Enquire |
|---|---|---|---|---|---|---|---|---|
| MTX-TROP2-302 | Multi-Cancers | MYE Symphony: A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors | Immunotherapy | TROP2 targeting. Low volume disease only. | Open - Recruiting | Myeloid Therapeutics | NCT05969041 | Enquire Now |
| DM002001 | Multi-Cancers | A Phase I, Multicentre, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM002 in Patients With Advanced Solid Tumors | Antibody Drug Conjugate | ADC targeting MUC1 and HER3 | Open - Recruiting | Xadcera Biopharmaceutical (Suzhou) Co., Ltd. | NCT06751329 | Enquire Now |
| SR-8541A-001 | Multi-Cancers | Phase 1, Dose Escalation, Safety, Tolerability, and Pharmacokinetic Study of SR-8541A (ENPP1 Inhibitor) Administered Orally as Monotherapy or in Combination With Checkpoint Inhibitors in Subjects With Advanced/Metastatic Solid Tumors | Targeted | PO small molecule ENPP1 inhibitor in combination of Nivolumab/Pembrolizumab (Introduction of ICI is after C2 onwards) | Open - Recruiting | Stingray Therapeutics | NCT06063681 | Enquire Now |
| SSGJ-709-101 | Multi-Cancers | A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Anti-tumor Activity of SSGJ-709 in Patients With Advanced Malignant Tumors | Immunotherapy | Anti-PD-1 and anti-LAG-3 bispecific antibody | Open - Recruiting | Shenyang Sunshine Pharmaceutical Co., LTD. | NCT07016490 | Enquire Now |
| NXT-9216-101 | Multi-Cancers | A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of NDI-219216 in Patients With Advanced Solid Tumors With/Without Microsatellite Instability and/or Deficient Mismatch Repair | Targeted | PO Small molecule inhibitor of WRN helicase activity - MSI-H/dMMR tumours | Open - Recruiting | Nimbus Wadjet, Inc. | NCT06898450 | Enquire Now |
| HRS-5041-103 | Prostate Cancer | A Phase I, Open-label, Multi-Center, Non-Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer | Targeted | PO AR-PROTAC molecule - AR degrader | Open - Recruiting | Atridia Pty Ltd | NCT06830850 | Enquire Now |
| ON-5001 | Multi-Cancers | A Phase 1 Dose-Escalation and Expansion Study of Intratumorally Administered ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas | Injectable Lesion | Intratumoral (IT) injection. PC7A nanoparticles loaded with cGAMP. Stimulator of interferon genes. | Closed | OncoNano Medicine, Inc. | NCT06022029 | Enquire Now |
| SRG-514-01 | Breast Cancer | A Phase 1 Study of SRG-514 Administered Intraoperatively to the Site of Tumor Resection of Patients Undergoing Breast-Conserving Cancer Surgery | NSAID Gel | Intraoperative administration into breast cavity. Newly diagnosed BCa patients. Gel Ketorolac (NSAID by blocking cyclooxygenase (COX) enzymes). | Open - Recruiting | SURGE Therapeutics | NCT06300411 | Enquire Now |
| A001 | Multi-Cancers | A Phase 1, First-in-human Study of Cabotamig (ARB202), Bispecific Antibody to CDH17 and CD3 in Advanced Gastrointestinal Malignancies | Immunotherapy | CDH17 targeting IO. | Closed | Arbele Pty Ltd | NCT05411133 | Enquire Now |
| CP-IVX001 | Multi-Cancers | A Phase 1 Open-label, Non-randomized, Multi-cohort Clinical Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours | Injectable Lesions | Ovarian, Gastric and CRC only. Must have Injectable lesions. Intratumoral injection. Live EchoVirus, No GMO component. | Open - Recruiting | ImmVirx PtyLtd | NCT05427487 | Enquire Now |
| CP-AU-007-01 | Multi-Cancers | A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer | Immunotherapy | IL-2 and Inhibits IL-2Rα Binding in combo. | Open - Recruiting | Aulos Bioscience, Inc. | NCT05267626 | Enquire Now |
| DCSZ11-101 | Multi-Cancers | A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors | Immunotherapy | Anti-CD93 monoclonal antibody, as a monotherapy and in combination with pembro. | Closed | DynamiCure Biotechnology | NCT05785754 | Enquire Now |
| HMBD-001-103 | Multi-Cancers | A Phase 1b Study to Evaluate HMBD-001 in Combination With Docetaxel With or Without Cetuximab in Participants With Advanced Squamous Non-Small Cell Lung Cancers, and HMBD-001 in Combination With Cetuximab in Participants With Advanced Squamous Cell Cancers | Targeted | Humanized IgG1 anti-HER3 monoclonal antibody + Combo treatment for squamous HER3 Mutation. | Open - Recruiting | Hummingbird Bioscience | NCT05910827 | Enquire Now |
| PSMA-007-001 | Castrate-Resistant Prostate Cancer | A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer | Immunotherapy | PSMA targeting BiTE. | Open - Recruiting | Janux Therapeutics | NCT05519449 | Enquire Now |
| GRWD5769-ST-01 | Multi-Cancers | A Modular, Multi-part, Multi-arm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD5769 Alone and in Combination With Anticancer Treatments in Patients With Solid Malignancies | Immunotherapy | Novel EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial – 1). | Open - Recruiting | Grey Wolf Therapeutics Pty Ltd | NCT06923761 | Enquire Now |
| NST-628-001 | Multi-Cancers | A Phase I, Open Label Single-arm Two-part Study to Investigate Safety, Pharmacokinetics, and Preliminary Efficacy of Pan-RAF/MEK Glue NST-628 Oral Tablets in Subject With Solid Tumors Harboring Genetic Alterations in the MAPK Pathway and With Other Solid Tumors | Targeted | MAPK pathway mutated/dependent advanced solid tumors. | Open - Recruiting | Nested Therapeutics, Inc | NCT06326411 | Enquire Now |
| AWT020-001 | Multi-Cancers | A Phase 1/2, First-in-human, Open-label Study of Single-agent AWT020 in Patients With Progressive Locally Advanced or Metastatic Cancer | Immunotherapy | Anti-PD1 IL-2 BiTE. | Open - Recruiting | Anwita Biosciences | NCT06092580 | Enquire Now |
| INI-4001-101 | Multi-Cancers | An Open-label, Multiple-Ascending Dose, Two-Part Dose Ranging and Cohort Expansion Study of INI-4001 in Patients With Advanced Solid Tumours | Immunotherapy | Small molecule TLR7/8 agonist. | Open - Recruiting | Inimmune Corporation | NCT06302426 | Enquire Now |
| PTT-4256-01 | Multi-Cancers | A Modular, Open Label, Dose Finding, Phase 1/2 Clinical Trial in Patients With Solid Tumours to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of PTT-4256. | Immunotherapy | Inhibitor of the pH-sensing G-protein-coupled receptor 65 | Open - Recruiting | Pathios Therapeutics Pty Ltd | NCT06634849 | Enquire Now |
| YH32367-101 | Multi-Cancers | A Phase 1/2, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of YH32367 in Patients With HER2-Positive Locally Advanced or Metastatic Solid Tumors | Targeted | HER2/4-1BB bispecific antibody. Targets HER2 and h4-1BB and binds to both targets. | Open - Recruiting | Yuhan Corporation | NCT05523947/a> | Enquire Now |
| D3S-002-100 | Multi-Cancers | A Phase 1, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose of D3S-002 Monotherapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations | Targeted | Mitogen-Activated Protein Kinase (MAPK) pathway mutation targeting. | Open - Recruiting | D3 Bio (Wuxi) Co., Ltd | NCT05886920 | Enquire Now |
| JS125-001-I | Multi-Cancers | A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of WJ47156 Monotherapy and in Combination With Other Anti-Tumor Therapies in Patients With Advanced Malignant Solid Tumors | Targeted | MSI high Colorectal Ca. PO in IV combo. IP selectively inhibiting the enzymatic activity of HDAC. | Closed | Shanghai Junshi Bioscience Co., Ltd. | NCT06571422 | Enquire Now |
| BM230-01 | Multi-Cancers | A Phase I, Multicenter, Non-randomized, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BM230 in Patients With Advanced Solid Tumors | Targeted | All with HER2. Subcutaneous injection. Bispecific antibody that specifically activates NK cells. Strongly binds to HER2 and CD16A. | Open - Recruiting | Suzhou Biomissile Pharmaceuticals Co., Ltd. | NCT06644300 | Enquire Now |
| ADCE-T02-01 | Multi-Cancers | First-in-Human, Phase 1 Study of ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors | Antibody Drug Conjugate | ADC targeting a tissue factor. | Open - Recruiting | Adcendo ApS | NCT06597721 | Enquire Now |
| AMT-116-01 | Multi-Cancers | First-in-Human, Phase 1 Study of AMT-116 in Patients With Advanced Solid Tumors | Antibody Drug Conjugate | Anti-CD44v9 Antibody-Drug Conjugate | Open - Recruiting | Multitude Therapeutics Inc. | NCT05725291 | Enquire Now |
| AMT-253-01 | Multi-Cancers | First-in-Human, Phase 1 Study of AMT-253, in Patients With Advanced Solid Tumors | Antibody Drug Conjugate | Anti MUC18 Antibody-Drug Conjugate | Open - Recruiting | Multitude Therapeutics (Australia) Pty Ltd | NCT05906862 | Enquire Now |